ロード中...
Acetylcholinesterase inhibitor treatment for myasthenia gravis
BACKGROUND: In myasthenia gravis, antibody‐mediated blockade of acetylcholine receptors at the neuromuscular junction abolishes the naturally occurring ‘safety factor’ of synaptic transmission. Acetylcholinesterase inhibitors provide temporary symptomatic treatment of muscle weakness but there is co...
保存先:
| 出版年: | Cochrane Database Syst Rev |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Ltd
2014
|
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7390275/ https://ncbi.nlm.nih.gov/pubmed/25310725 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD006986.pub3 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|